RCS - Oxford Nanopore Tech - Oxford Nanopore: Singapore Precision Medicine prog

Oxford Nanopore TechnologiesAnnouncement

05/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240805:nRSE1396Za&default-theme=true

RNS Number : 1396Z  Oxford Nanopore Technologies plc  05 August 2024

5 August 2024

Oxford Nanopore Technologies plc

Oxford Nanopore to sequence 10,000 genomes for Singapore's National Precision
Medicine (NPM) programme

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the Company
delivering a new generation of nanopore-based molecular sensing technology,
notes the announcement of a landmark project with Singapore's National
Precision Medicine (NPM) programme, led by Precision Health Research,
Singapore (PRECISE), to sequence 10,000 genomes representing Singapore's
diverse population, including Malay, Indian and Chinese communities.

The project is aimed at developing a catalogue of structural variants that
have demonstrated significance in helping clinician scientists and researchers
in understanding human genetic diversity and diseases. The Oxford Nanopore
platform was selected by the NPM programme through a competitive process
because of its scalability and flexibility in sequencing both short and
ultra-long DNA/RNA fragments, including detection of methylation, without the
need for additional steps and at speeds faster than other platforms.

This initiative underscores Oxford Nanopore's commitment to advancing genetic
research and healthcare outcomes on a global scale, particularly for
ethnically diverse populations that are typically underrepresented in genomic
databases.

The project started mid-2024 and is expected to run for c.12 months. There is
no change to the Company's already stated 2024 and medium-term financial
guidance.

Gordon Sanghera, CEO of Oxford Nanopore commented:

"We are excited to collaborate with Singapore's National Precision Medicine
(NPM) programme to create one of the most extensive and inclusive reference
genome datasets globally. This collaboration not only enhances our commitment
to precision healthcare but also strategically positions Singapore as a
pivotal hub for genomics in the Asia Pacific, fostering significant
advancements in medical research and healthcare outcomes."

Read more about the project here:
https://nanoporetech.com/news/singapore-s-national-precision-medicine-npm-programme-engages-oxford-nanopore-to-advance-understanding-of-the-genetics-of-singapore-s-multi-ethnic-population
(https://nanoporetech.com/news/singapore-s-national-precision-medicine-npm-programme-engages-oxford-nanopore-to-advance-understanding-of-the-genetics-of-singapore-s-multi-ethnic-population)

 ENDS 

 

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:         ir@nanoporetech.com (mailto:ir@nanoporetech.com)

Media:              media@nanoporetech.com
(mailto:media@nanoporetech.com)

 

Teneo (communications adviser to the Company)

Tom Murray, Olivia Peters

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com
(mailto:OxfordNanoporeTechnologies@teneo.com)

 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The company
has developed a new generation of nanopore-based sensing technology that is
currently used for real-time, high-performance, accessible, and scalable
analysis of DNA and RNA.  The technology is used in more than 120 countries,
to understand the biology of humans, plants, animals, bacteria, viruses and
environments as well as to understand diseases such as cancer. Oxford
Nanopore's technology also has the potential to provide broad, high impact,
rapid insights in a number of areas including healthcare, food and
agriculture.

 

Oxford Nanopore devices sequence DNA and RNA directly and sequence short to
ultra-long fragments of DNA, for a truly comprehensive picture of the genome.
Data is streamed in real-time and can enable rapid insights.  The technology
is fully scalable - from pocket-sized to ultra-high throughput devices.

For more information please visit: www.nanoporetech.com
(http://www.nanoporetech.com)

 

About Precision Health Research, Singapore (PRECISE):

Precision Health Research, Singapore (PRECISE) is the central entity set up to
coordinate a whole of Singapore effort to implement Phase II of Singapore's
three-phase National Precision Medicine (NPM) programme.

 

NPM Phase II aims to transform healthcare in Singapore and improve patient
outcomes through new insights into the Asian genome and data-driven healthcare
solutions. In NPM Phase II, PRECISE will collaborate with Singapore research
and clinical partners, including the Agency for Science, Technology and
Research (A*STAR), Lee Kong Chian School of Medicine, National Healthcare
Group, National University Health System, National University of Singapore,
and SingHealth Duke-NUS  Academic Medical Centre to study the genetic makeup
of 100,000 healthy Singaporeans and specific patient cohorts. The genetic data
will be integrated with detailed lifestyle, environmental, and clinical data
to yield rich insights into factors that contribute to Asian diseases and
conditions.

 

Additionally, NPM Phase II will enhance the breadth and depth of the
Precision Medicine-related industry by attracting and anchoring overseas
companies in Singapore, while yielding new opportunities for home-grown
companies. To enhance and accelerate the precision medicine sector, PRECISE
works in close collaboration with A*STAR, the Biomedical Sciences Industry
Partnership Office, and the Economic Development Board to catalyse the next
phase of growth for Singapore's healthcare and the biomedical technology
industries.

 

PRECISE is a programme of the Consortium for Clinical Research and Innovation,
Singapore (CRIS). PRECISE is supported by the National Research Foundation,
Singapore (NRF) under the RIE2020 White Space (MOH-000588 and MOH-001264) and
administered by the Singapore Ministry of Health through the National Medical
Research Council (NMRC) Office, MOH Holdings Pte Ltd

 

For more information, visit www.npm.sg (http://www.npm.sg)

 

Forward-looking statements

This announcement contains certain forward-looking statements. For example,
statements regarding expected revenue growth and profit margins are
forward-looking statements. Phrases such as "aim", "plan", "expect", "intend",
"anticipate", "believe", "estimate", "target", and similar expressions of a
future or forward-looking nature should also be considered forward-looking
statements. Forward-looking statements address our expected future business
and financial performance and financial condition, and by definition address
matters that are, to different degrees, uncertain. Our results could be
affected by macroeconomic conditions, the COVID-19 pandemic, delays in our
receipt of components or our delivery of products to our customers,
suspensions of large projects and/or acceleration of large products or
accelerated adoption of pathogen surveillance. These or other uncertainties
may cause our actual future results to be materially different than those
expressed in our forward-looking statements.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPAMATMTTMMJI